• Explore /
  • Poster
  • / NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients.

NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients.

Abstract Video & Slides Poster

Authors

null

Angela Damato

Medical Oncology Unit. Clinical Cancer Center. AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy

Angela Damato , Francesco Iachetta , Nicola Normanno , Francesca Bergamo , Evaristo Maiello , Alberto Zaniboni , Lorenzo Antonuzzo , Guglielmo Nasti , Giuseppe Tonini , Roberto Bordonaro , Francesca Di Fabio , Alessandra Romagnani , Annalisa Berselli , Carmine Pinto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT04072198

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS4118)

DOI

10.1200/JCO.2020.38.15_suppl.TPS4118

Abstract #

TPS4118

Poster Bd #

110

Abstract Disclosures

Similar Posters

First Author: Angela Damato

First Author: Anne Hansen Ree

First Author: Arturo Loaiza-Bonilla

First Author: Johanna C. Bendell